Inovio Pharmaceuticals Inc (INO)
Drugs • Health Care
July 30, 2026 INOVIO Pharmaceuticals Inc. Announces $20 Million Public Offering Inovio Pharmaceuticals has announced a public offering to raise $20 million, which will fund its DNA medicine initiatives targeting HPV-related diseases and cancer. The offering includes common stock and warrants, with potential additional shares available to the underwriter. This move is expected to enhance the company's growth in the biotech sector.
May 28, 2026 Inovio Pharmaceuticals to Showcase Innovations at Upcoming Conferences Inovio Pharmaceuticals is set to present at the Jefferies Global Healthcare Conference and the World Orphan Drug Congress, highlighting its DNA medicine innovations. The company will engage with investors and discuss its strategic vision for addressing major health challenges.
May 21, 2026 INOVIO Pharmaceuticals Reports Positive Phase 3 Results for VGX-3100 in Cervical Dysplasia INOVIO Pharmaceuticals reports positive results from a Phase 3 trial of VGX-3100, targeting cervical dysplasia associated with high-risk HPV types. The trial showed significant efficacy and safety, paving the way for regulatory submissions in China and highlighting the potential of innovative DNA therapies.
May 08, 2026 Inovio Pharmaceuticals Announces Participation in Key Scientific Conferences Inovio Pharmaceuticals will present innovative research at the American Society of Gene and Cell Therapy and the American Society of Clinical Oncology meetings. Their focus includes gene therapy for hemophilia A and immunotherapy for recurrent respiratory papillomatosis.
May 01, 2026 Inovio Pharmaceuticals Set to Release Q1 2026 Financial Results Inovio Pharmaceuticals is set to release its Q1 2026 financial results on May 13, followed by a conference call to discuss performance and strategic direction. The company focuses on DNA-based therapies for HPV and other diseases, emphasizing transparency with stakeholders.
April 07, 2026 Inovio Pharmaceuticals Inc Faces Class Action Lawsuit Amid Allegations of Misleading Investors Inovio Pharmaceuticals is facing a class action lawsuit for allegedly misleading investors about its CELLECTRA device and regulatory challenges. The lawsuit, initiated by the Rosen Law Firm, highlights significant manufacturing deficiencies and overstated prospects for the company's INO-3107 product, raising concerns about its viability and investor losses.
April 07, 2026 Inovio Pharmaceuticals Faces Class Action Deadline Amid Regulatory Setbacks Inovio Pharmaceuticals is facing a class action lawsuit with a deadline of April 7, 2026, due to allegations of misleading statements about its product INO-3107. Key accusations include deficient manufacturing practices and insufficient data for FDA approval, leading to a significant drop in stock price. Investors are encouraged to consider participating in the lawsuit as the situation develops.
April 02, 2026 INOVIO Pharmaceuticals Announces Proposed Public Offering INOVIO Pharmaceuticals has proposed a public offering of its common stock to strengthen its financial position for developing innovative DNA medicines. The offering is contingent on market conditions and is managed by Piper Sandler. This initiative follows a recent SEC registration and signifies INOVIO's commitment to advancing healthcare solutions.
April 02, 2026 INOVIO Pharmaceuticals Announces $17.5 Million Public Offering INOVIO Pharmaceuticals has launched a public offering to raise $17.5 million through shares and warrants, aiming to enhance its R&D in DNA medicines. This strategic move is expected to support advancements in treatments for HPV-related diseases, cancer, and infectious diseases, reflecting growing investor interest in biotech.
April 01, 2026 Inovio Pharmaceuticals to Showcase Innovations at World Federation of Hemophilia Congress Inovio Pharmaceuticals will present its innovative DNA medicine research at the World Federation of Hemophilia Congress in Kuala Lumpur. Key presentations will cover new approaches to Factor VIII replacement therapies, showcasing transformative solutions for hemophilia patients.
March 20, 2026 Inovio Pharmaceuticals Faces Class Action Amid Regulatory Setbacks Inovio Pharmaceuticals is facing a class action lawsuit for allegedly misleading investors about its CELLECTRA device and the regulatory approval of its INO-3107 treatment. The lawsuit claims the company failed to disclose manufacturing deficiencies and delayed FDA submissions, leading to significant stock price drops. Shareholders are encouraged to participate in the lawsuit as deadlines approach.
March 12, 2026 INOVIO Pharmaceuticals Reports Q4 and Full Year 2025 Financial Results INOVIO Pharmaceuticals has announced its financial results for Q4 and full year 2025, highlighting the FDA review of INO-3107 and ongoing advancements in cancer treatments. The company aims to optimize resources in preparation for potential commercialization while managing its financial outlook.
March 12, 2026 Inovio Pharmaceuticals Inc. Reports 2025 Annual Results: Navigating Challenges and Opportunities Inovio Pharmaceuticals reported significant milestones and challenges in 2025, focusing on the development of INO-3107 for HPV-related diseases. The company faced financial hurdles, including a net loss of $84.94 million, while seeking additional funding to support ongoing operations and product development.
March 09, 2026 Inovio Pharmaceuticals Set to Showcase Innovations at Upcoming Scientific Conferences Inovio Pharmaceuticals is set to present its latest research on DNA medicines at two important scientific conferences, focusing on HPV treatment and COVID-19 solutions. Their presentations promise to highlight innovative therapies that could transform patient care.
March 05, 2026 Inovio Pharmaceuticals Set to Release Q4 and Full Year 2025 Financial Results Inovio Pharmaceuticals is set to release its 2025 Q4 and annual financial results on March 12, 2026. A live conference call will follow, providing insights into the company's performance and strategic direction.
March 04, 2026 Inovio Pharmaceuticals and Akeso Team Up to Tackle Glioblastoma with Innovative Combination Therapy Inovio Pharmaceuticals and Akeso Inc. have partnered to develop a novel combination therapy for glioblastoma, leveraging Inovio's DNA technology and Akeso's monoclonal antibodies. Early-stage clinical trials aim to evaluate the safety and effectiveness of this promising approach, potentially transforming treatment options for GBM patients.
February 20, 2026 Inovio Pharmaceuticals Faces Securities Fraud Lawsuit Amid Regulatory Setbacks Inovio Pharmaceuticals is embroiled in a securities fraud lawsuit following a sharp decline in stock prices linked to regulatory delays and misleading statements. Investors are urged to act quickly as the deadline for filing claims approaches.
February 19, 2026 Inovio Pharmaceuticals Faces Class Action Lawsuit Amid Regulatory Setbacks Inovio Pharmaceuticals is facing a class action lawsuit due to regulatory issues surrounding its treatment INO-3107, which has seen significant delays. Shareholders who incurred losses from October 2023 to December 2025 are urged to act before the April 2026 deadline to potentially serve as lead plaintiffs.
February 18, 2026 Inovio Pharmaceuticals Faces Securities Fraud Class Action Amid Regulatory Setbacks Inovio Pharmaceuticals is facing a class action lawsuit for alleged securities fraud due to misleading statements regarding its regulatory processes. The lawsuit addresses significant delays in the approval of its investigational treatment, INO-3107, and claims of overstated business prospects, leading to substantial investor losses. Shareholders are urged to file claims by April 7, 2026.
February 17, 2026 Inovio Pharmaceuticals Faces Class Action Lawsuit Amid Securities Fraud Allegations Inovio Pharmaceuticals is facing a class action lawsuit alleging securities fraud related to misleading statements about its investigational treatment INO-3107. The lawsuit follows significant stock price declines after the company missed deadlines and faced FDA review setbacks. Affected investors are urged to file claims by April 7, 2026.
February 13, 2026 Inovio Pharmaceuticals Faces Class Action Lawsuit Amidst Securities Fraud Allegations Inovio Pharmaceuticals is under fire with a class action lawsuit alleging securities fraud after their stock dropped due to manufacturing issues and FDA review delays. Investors are encouraged to participate in the lawsuit before the April 2026 deadline.
February 12, 2026 Inovio Pharmaceuticals Faces Securities Fraud Investigation Amidst Stock Declines Inovio Pharmaceuticals is being investigated for potential securities fraud following significant stock declines linked to operational delays and FDA review timelines. Investors are urged to explore their legal rights as the situation unfolds.
February 12, 2026 Inovio Pharmaceuticals Faces Securities Fraud Investigation Inovio Pharmaceuticals is being investigated for potential securities fraud after significant stock declines due to delayed FDA submissions. The Law Offices of Frank R. Cruz are advising affected investors to consider legal claims. The situation underscores the volatility of biopharmaceutical investments.
February 12, 2026 Inovio Pharmaceuticals to Showcase Innovations at Key Conferences Inovio Pharmaceuticals will showcase its cutting-edge research at several key conferences, including updates on DNA immunotherapy for cancer and infectious diseases. The company aims to engage with investors and the scientific community, highlighting its commitment to advancing biotechnology.
February 12, 2026 Inovio Pharmaceuticals Faces Class Action Lawsuit Amid Securities Law Violations Allegations Inovio Pharmaceuticals is embroiled in a class action lawsuit alleging securities law violations related to misleading statements about its CELLECTRA device. Investors who purchased shares from October 10, 2023, to December 26, 2025, are encouraged to participate. The outcome of this case could have significant financial implications for the company and its shareholders.
February 11, 2026 Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Fraud Allegations Inovio Pharmaceuticals is currently facing a class action lawsuit due to allegations of securities fraud involving misleading statements about its CELLECTRA device and regulatory delays. Investors affected between October 10, 2023, and December 26, 2025, are encouraged to join the legal action before the April 7, 2026, deadline.
February 09, 2026 Inovio Pharmaceuticals Faces Class Action Lawsuit Amid Regulatory Concerns Inovio Pharmaceuticals is under legal scrutiny due to a class action lawsuit alleging misinformation about its CELLECTRA device's regulatory approval. The lawsuit claims the company misled investors about manufacturing issues and delayed FDA submissions, significantly impacting stock performance. Shareholders within the specified timeframe may participate in the lawsuit.
December 29, 2025 FDA Accepts INOVIO's BLA for INO-3107: A New Hope for RRP Treatment INOVIO Pharmaceuticals has received FDA acceptance for its BLA of INO-3107, a promising treatment for recurrent respiratory papillomatosis (RRP). Clinical trials show significant surgery reduction, highlighting its potential as a non-surgical option. The FDA review process will be closely watched as it may transform RRP treatment.
December 19, 2025 INOVIO Pharmaceuticals Inc. Announces Inducement Grant to New Employee Inovio Pharmaceuticals has announced an equity grant as part of its Inducement Plan, allowing a new employee to purchase 24,000 shares. This strategic move aims to enhance workforce alignment with shareholder goals and maintain compliance with Nasdaq regulations.
November 18, 2025 INOVIO Pharmaceuticals Set to Showcase Innovations at Upcoming Investor Conferences Inovio Pharmaceuticals will participate in two major investor conferences in December, focusing on its DNA medicines for HPV, cancer, and rare diseases. The events include a fireside chat and a panel discussion, providing insights into the company's strategic direction and advancements.
November 11, 2025 INOVIO Pharmaceuticals Inc. Announces $25 Million Public Offering INOVIO Pharmaceuticals has priced a public offering at $1.90 per share to raise $25 million, aiming to enhance its research in DNA medicines for HPV-related diseases and cancers. The offering, underwritten by the company, will support ongoing development and innovation in the biotech sector.
November 10, 2025 INOVIO Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Developments INOVIO Pharmaceuticals announced its Q3 2025 results, emphasizing the completion of its BLA submission for INO-3107, which targets recurrent respiratory papillomatosis. The company also reported a mixed financial outlook and plans to initiate further clinical trials, signaling strong progress in DNA medicine development.
November 10, 2025 INOVIO Pharmaceuticals Announces Proposed Public Offering Inovio Pharmaceuticals has announced a public offering of its common stock to raise funds for advancing its innovative DNA medicine initiatives. With Piper Sandler & Co. as the underwriter, the offering's success is contingent on market conditions, emphasizing the company's commitment to addressing HPV-related diseases and cancer.
November 10, 2025 Inovio Pharmaceuticals Inc. Reports Q3 2025 Financial Results: A Challenging Yet Promising Journey Inovio Pharmaceuticals reported its Q3 2025 financial results, revealing significant challenges with zero revenue and a net loss of $45.49 million. Despite these obstacles, the company made strides in clinical development, particularly with its lead candidate INO-3107, and continues to seek additional funding for its promising DNA medicines.
November 03, 2025 INOVIO Pharmaceuticals Advances Potential Treatment for RRP with BLA Submission INOVIO Pharmaceuticals has submitted a Biologics License Application for INO-3107, a DNA immunotherapy targeting recurrent respiratory papillomatosis (RRP). The company seeks FDA's Accelerated Approval, which could lead to the first DNA medicine for RRP treatment. Promising clinical trial results indicate substantial reductions in surgery needs for patients.
October 31, 2025 Inovio Pharmaceuticals Inc. Announces Equity Grant Under Inducement Plan Inovio Pharmaceuticals has issued an equity grant under its 2022 Inducement Plan to attract skilled talent. The grant includes stock options for a newly hired employee, aligning their interests with company growth and innovation in DNA medicines.
October 27, 2025 INOVIO Pharmaceuticals Prepares for Third Quarter 2025 Financial Results Inovio Pharmaceuticals is set to release its Q3 2025 financial results on November 10, 2025, with a live conference call to discuss performance and strategic initiatives. Investors will have access to insights into the company's advancements in DNA medicines for HPV and other diseases.
October 23, 2025 Inovio Pharmaceuticals to Showcase Innovations at Upcoming Virtual Conference Inovio Pharmaceuticals will present its latest innovations at the Stephens Biotechnology Virtual Fireside Chat Conference on November 4, 2025. The event allows investors to gain insights into the company's groundbreaking DNA medicines aimed at treating HPV-related diseases and various cancers.
October 21, 2025 INOVIO Pharmaceuticals Unveils Promising DMAb Results in Nature Medicine INOVIO Pharmaceuticals has published groundbreaking results from a Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs) for COVID-19 in *Nature Medicine*. The study highlights a robust safety profile and sustained efficacy, marking a significant advancement in biotechnology. This innovative technology could reshape treatment options for various diseases.
October 02, 2025 Inovio Pharmaceuticals Induces New Talent with Stock Option Grant On October 2, 2025, Inovio Pharmaceuticals granted stock options to a new employee as part of its strategy to attract and retain talent. This move aligns employee interests with company performance and reflects Inovio's commitment to innovation in DNA medicines.
September 25, 2025 Inovio Pharmaceuticals: Pioneering DNA Medicines with Upcoming Scientific Presentations Inovio Pharmaceuticals is pioneering DNA medicines with its lead candidate INO-3107 for treating Recurrent Respiratory Papillomatosis. The company will present at key conferences, highlighting advancements in treatment and innovative DNA technology.
August 26, 2025 INOVIO Pharmaceuticals Initiates Rolling Submission for INO-3107 to Treat Recurrent Respiratory Papillomatosis INOVIO Pharmaceuticals has begun a rolling submission for its investigational therapy INO-3107, targeting recurrent respiratory papillomatosis (RRP). The therapy shows promise in reducing the need for surgeries in patients, with significant immune responses observed in trials. This marks a vital step in addressing the treatment gap for this rare disease.
August 25, 2025 Inovio Pharmaceuticals Sets the Stage for Investor Engagement at H.C. Wainwright Conference Inovio Pharmaceuticals will participate in the H.C. Wainwright Conference, showcasing its DNA medicine innovations for HPV and cancer treatment. A pre-recorded presentation will be available, allowing investors to engage with Inovio's strategic developments. Additionally, in-person meetings with management will foster direct communication.
August 12, 2025 Inovio Pharmaceuticals Inc. Reports Q2 2025 Financial Results: Challenges and Opportunities Ahead Inovio Pharmaceuticals reported zero revenue for Q2 2025 and a net loss of $23.51 million, highlighting ongoing financial challenges. Despite setbacks with product development, the company is focused on advancing its clinical trials and securing necessary funding.
August 12, 2025 INOVIO Pharmaceuticals Reports Strong Q2 2025 Financial Results and Key Progress on INO-3107 INOVIO Pharmaceuticals has released its Q2 2025 financial results, revealing improved metrics and significant progress on its lead candidate, INO-3107, for RRP treatment. The company plans to submit a BLA for INO-3107, leveraging its Breakthrough Therapy designation to expedite FDA review.
August 11, 2025 INOVIO Pharmaceuticals Reports Promising Long-Term Results for INO-3107 in Treating Recurrent Respiratory Papillomatosis INOVIO Pharmaceuticals reports promising long-term results for INO-3107, significantly reducing surgeries required for recurrent respiratory papillomatosis. This breakthrough treatment, leveraging DNA medicine technology, has the potential to redefine care for affected patients.
August 04, 2025 INOVIO Pharmaceuticals Set to Release Q2 2025 Financial Results Inovio Pharmaceuticals is set to release its Q2 2025 financial results on August 12, 2025. Following the announcement, a live conference call will provide insights into the company's performance and strategic direction.
July 07, 2025 INOVIO Pharmaceuticals Set to Present at Orphan Drug Summit INOVIO Pharmaceuticals will present at the Orphan Drug Summit on July 16, showcasing its DMAb Technology in DNA medicine for rare diseases. The company aims to enhance treatment options for underserved patient populations through innovation.
July 03, 2025 Inovio Pharmaceuticals Announces $25 Million Public Offering Inovio Pharmaceuticals has announced a $25 million public offering of common stock and warrants to strengthen its financial base for developing DNA medicines. The offering includes options for underwriters to purchase additional shares, reflecting confidence in the company's strategic direction and future prospects.
July 02, 2025 INOVIO Pharmaceuticals Announces Proposed Public Offering INOVIO Pharmaceuticals has announced a public offering of its common stock to strengthen its financial position and support research in DNA medicines. The offering includes shares and various warrants, with Piper Sandler & Co. as the lead underwriter.
May 13, 2025 Inovio Pharmaceuticals Inc. Reports Q1 2025 Financial Results: Progress Amid Challenges Inovio Pharmaceuticals has released its Q1 2025 financial results, reporting a revenue increase to $65,000 while facing significant operating losses. Despite these challenges, progress in product development, including plans for a Biologic License Application submission, highlights the company's potential for future growth.
May 13, 2025 Inovio Pharmaceuticals Reports First Quarter 2025 Financial Results and Progress Update Inovio Pharmaceuticals announced its Q1 2025 financial results, highlighting advancements in its INO-3107 BLA submission and promising data from its DMAb technology trials. The company reported a significant reduction in operating expenses, reflecting a strategic focus on efficiency.
April 30, 2025 Inovio Pharmaceuticals Set to Showcase Breakthroughs in DNA Medicines at Key Conferences Inovio Pharmaceuticals is set to present groundbreaking data on its DNA medicines at several key conferences in May 2025, particularly highlighting INO-3107 for HPV-related diseases. These presentations aim to engage investors and the scientific community, showcasing Inovio’s innovative approaches and potential impacts on treatment methods.
April 29, 2025 Inovio Pharmaceuticals Set to Unveil Q1 2025 Financial Results Inovio Pharmaceuticals is set to release its Q1 2025 financial results on May 13, 2025. A live conference call will follow the announcement, allowing for stakeholder engagement and insights into the company's performance.
April 09, 2025 INOVIO Pharmaceuticals to Showcase Breakthrough Data at Upcoming Scientific Conferences Inovio Pharmaceuticals is set to showcase pivotal advancements in HPV-related treatments and DNA medicine at major scientific conferences. Their lead candidate, INO-3107, demonstrates a promising 72% response rate for treating recurrent respiratory papillomatosis, highlighting the company's innovative approach to healthcare solutions.
March 18, 2025 Inovio Pharmaceuticals Inc. Reports 2024 Annual Results: A Year of Challenges and Strategic Developments Inovio Pharmaceuticals' 2024 report reveals significant operational changes, a net loss of $104.1 million, and ongoing challenges in product development. The company aims to secure additional funding and navigate legal disputes while advancing its DNA medicines.
March 18, 2025 Inovio Pharmaceuticals Reports Strong Progress in 2024 Financial Results and Operational Highlights Inovio Pharmaceuticals announced its 2024 financial results, showcasing advancements in its DNA medicine pipeline, particularly INO-3107 for HPV-related diseases. The company is preparing for an FDA submission and reports promising clinical trial data across several candidates, positioning itself for growth in the biotech sector.
March 13, 2025 INOVIO Pharmaceuticals Reports Groundbreaking Interim Results in DMAb Trial for COVID-19 INOVIO Pharmaceuticals reported groundbreaking interim results from its Phase 1 trial of DNA-encoded monoclonal antibodies for COVID-19, demonstrating 100% durability in antibody production and a favorable safety profile. The findings suggest that this innovative technology could revolutionize antibody treatments and address existing challenges in therapeutic delivery.
March 12, 2025 Inovio Pharmaceuticals Set to Release Q4 and Year-End 2024 Financial Results Inovio Pharmaceuticals is set to report its Q4 and year-end 2024 financial results on March 18, 2025. The announcement will be followed by a live conference call providing insights into the company's performance, particularly in its fight against HPV and infectious diseases. Investors can access the webcast for a detailed overview and Q&A session.
February 19, 2025 SWOT Analysis of Inovio Pharmaceuticals Inc. in 2025 This SWOT analysis reviews Inovio Pharmaceuticals Inc. as of 2025, detailing its innovative strengths and significant financial weaknesses. It outlines opportunities in the biotech market while addressing threats from competition and regulatory challenges.
February 12, 2025 INOVIO Pharmaceuticals Unveils Promising Clinical Results for INO-3107 in RRP Treatment INOVIO Pharmaceuticals' INO-3107 has shown significant efficacy in treating recurrent respiratory papillomatosis (RRP), reducing the need for surgeries in the majority of patients. The Phase 1/2 trial results, published in *Nature Communications*, highlight the potential of this DNA medicine to transform RRP treatment and improve patients' quality of life.
February 10, 2025 Inovio Pharmaceuticals to Showcase Promising Data on INO-3107 at Upcoming AACR-IO Conference Inovio Pharmaceuticals is set to present data on INO-3107, an investigational therapy targeting HPV-related diseases, at the AACR-IO Conference. Their findings could significantly impact treatment approaches and attract interest in the biotech community.
November 14, 2024 Inovio Pharmaceuticals Inc. Releases Q3 2024 Financial Report: Challenges and Strategic Developments Inovio Pharmaceuticals released its Q3 2024 financial report, revealing zero revenue and a net loss of $25.16 million. Despite operational challenges, the company continues to invest in R&D and has partnerships aimed at advancing its product candidates.
August 08, 2024 Inovio Pharmaceuticals Inc. Reports Q2 2024 Financial Results: A Mixed Bag Amidst Ongoing Challenges Inovio Pharmaceuticals' Q2 2024 results reveal a decline in revenue to $101,000 and a net loss of $54.8 million, despite reduced expenses. The company is advancing its product pipeline and exploring funding options for future growth amidst ongoing challenges.
May 13, 2024 Inovio Pharmaceuticals Inc. Reports 2024 Q1 Financial Results: A Focus on Future Growth Inovio Pharmaceuticals reported its Q1 2024 financial results, showing improved net loss and reduced expenses. The company closed a $33.2 million offering, enhancing its cash position for ongoing R&D. Inovio continues to advance its promising DNA medicine pipeline.